Researchers at Queen Mary University of London (QMUL) have developed a way of assembling organic molecules into complex tubular tissue-like structures without the use of moulds or techniques like 3D printing.
The study, which will appear on Monday 28 September in the journal Nature Chemistry, describes how peptides and proteins can be used to create materials that exhibit dynamic behaviors found in biological tissues like growth, morphogenesis, and healing.
The method uses solutions of peptide and protein molecules that, upon touching each other, self-assemble to form a dynamic tissue at the point at which they meet. As the material assembles itself it can be easily guided to grow into complex shapes.
This discovery could lead to the engineering of tissues like veins, arteries, or even the blood-brain barrier, which would allow scientists to study diseases such as Alzheimer’s with a high level of similarity to the real tissue, which is currently impossible. The technique could also contribute to the creation of better implants, complex tissues, or more effective drug screening methods.
Alvaro Mata, Director of the Institute of Bioengineering at QMUL and lead author of the paper, said: “What is most exciting about this discovery is the possibility for us to use peptides and proteins as building-blocks of materials with the capacity to controllably grow or change shape, solely by self-assembly.
The Latest on: Protein/peptide system
via Google News
The Latest on: Protein/peptide system
- Origin of Life Theory Involving RNA–Protein Hybrid Gets New Supporton May 18, 2022 at 11:18 am
Chemists say they have solved a crucial problem in a theory of life’s beginnings, by demonstrating that RNA molecules can link short chains of amino acids together. The findings, published on 11 May ...
- Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007on May 18, 2022 at 5:00 am
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it ...
- AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meetingon May 18, 2022 at 4:00 am
(Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and ...
- Viruses Target Super-Short Protein Motifs to Disrupt Host Biologyon May 16, 2022 at 10:28 pm
Only recently appreciated as critical components of cellular functions, unstructured stretches of amino acids called SLiMs are key to viral-host interactions.
- Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetingson May 16, 2022 at 11:03 am
Presenting new data on ’1104 in allergic disease at the American Thoracic Society International Conference in San Francisco on May 17 Delivering an oral presentation on resetting the immune system to ...
- Protein Labeling Market Size, Share, Trends, And Industry Forecast 2022 - 2031on May 12, 2022 at 1:42 am
Because of their small size, nanoparticles can reach complex sites and form covalent bonds with target proteins or peptides for better labeling and stability. North America led the protein label ...
- Skin Cancer Cells Depend on Alzheimer’s Protein To “Take Root” in the Brainon May 10, 2022 at 5:04 pm
Amyloid beta (Aβ) is a peptide derived from amyloid precursor protein (APP). A build-up of Aβ in specific ... (murine melanoma cells injected into mice with a complete immune system). If Aβ ...
- Revolo Biotherapeutics to Lead Panel Discussion on the Future of Autoimmune Disease Treatmenton May 10, 2022 at 5:07 am
‘1104 is a first-in-class peptide derived from a natural immune-regulatory protein, mTB Chaperonin 60.1 that is involved in resetting the immune system. Revolo Bio is advancing ‘1104 through two Phase ...
- Small changes -- but essential! How peptides are recognized in receptorson May 5, 2022 at 1:01 pm
This is because a novel test system showed that the peptides use different 'docking pathways' and that this can lead to different signals in the cell. The flexibility and mobility of the complexes ...
via Bing News